Clinical trial · Interventional
Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection
Association Between Autologous Transfusion and Recurrence-free Survival in Patients With Hepatocellular Carcinoma After Resection-a Prospective Non-randomized Controlled Trial
NCT02654028CI-TRIAL-00063420AT/HCCcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective non-randomized controlled trial aims to determine whether autotransfusion of red blood cells salvaged before liver resection is associated with the recurrence-free survival in patients with hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autotransfusion | Procedure | — | UNRESOLVED |
| Control group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Autotransfusion group
- description
- These group of patients will receive autotransfusion before liver resection.
- interventionNames
- Procedure: Autotransfusion
- type
- ACTIVE_COMPARATOR
- label
- Control group
- description
- These group of patients will not receive autotransfusion before liver resection.
- interventionNames
- Other: Control group
Primary outcomes (1)
- measure
- Number of participants with tumor recurrence
- timeFrame
- 1-year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who underwent liver resection; * Diagnosis of hepatocellular carcinoma confirmed by postoperative histopathology; * Level of preoperative hemoglobin ≥110 g/L; * Child-Pugh class A or B liver function; * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Exclusion Criteria: * A history of other malignancies; * History of active autoimmune or immunodeficiency diseases; * Concurrent cardiac, pulmonary, cerebral, or renal dysfunction; * Loss to follow-up.
References
Publications (3)
- BACKGROUNDHan S, Kim G, Ko JS, Sinn DH, Yang JD, Joh JW, Lee SK, Gwak MS. Safety of the Use of Blood Salvage and Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma. Ann Surg. 2016 Aug;264(2):339-43. doi: 10.1097/SLA.0000000000001486. PMID 26501715
- BACKGROUNDTomimaru Y, Eguchi H, Wada H, Hama N, Kawamoto K, Kobayashi S, Umeshita K, Doki Y, Mori M, Nagano H. Predicting the necessity of autologous blood collection and storage before surgery for hepatocellular carcinoma. J Surg Oncol. 2013 Dec;108(7):486-91. doi: 10.1002/jso.23426. Epub 2013 Sep 5. PMID 24009154
- BACKGROUNDKwon JH, Han S, Kim D, Kuk JH, Cho H, Kim S, Yang JD, Kim C, Kim JM, Choi GS, Joh JW, Ko JS, Gwak MS, Kim G. Blood Salvage and Autotransfusion With Single Leukoreduction Does Not Increase the Risk of Tumor Recurrence After Liver Transplantation for Advanced Hepatocellular Carcinoma. Ann Surg. 2022 Dec 1;276(6):e842-e850. doi: 10.1097/SLA.0000000000004866. Epub 2021 Mar 18. PMID 33914466